PRECLINICAL ANTITUMOR ACTIVITY OF THIARABINE IN HUMAN LEUKEMIA AND LYMPHOMA XENOGRAFT MODELS

被引：3

作者：

Waud, William R. ^{[1
]}

Gilbert, Karen S. ^{[1
]}

Secrist, John A., III ^{[1
]}

机构：

[1] So Res Inst, Canc Therapeut & Immunol Dept, Birmingham, AL 35255 USA

来源：

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS | 2012年 / 31卷 / 09期

关键词：

Thiarabine; leukemia; lymphoma; ara-C; clofarabine; fludarabine monophosphate; cladribine; gemcitabine; 4'-THIO-BETA-D-ARABINOFURANOSYLCYTOSINE 4'-THIO-ARA-C; GEMCITABINE; P388;

D O I：

10.1080/15257770.2012.710768

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Thiarabine was evaluated for antitumor activity in seven human leukemia, lymphoma, and myeloma xenograft models to explore the activity in hematological malignancies. Thiarabine was active against all of the human leukemia and lymphoma lines tested, being curative against HL-60 leukemia and AS283 lymphoma and effecting tumor regressions in CCRF-CEM, MOLT-4, and K-562 leukemia and RL lymphoma models, but did not exhibit any appreciable activity against RPMI-8226 myeloma. For the leukemia/lymphoma models, thiarabine was more efficacious than ara-C/palmO-ara-C (four models), clofarabine (three models), fludarabine monophosphate (five models), cladribine (four models), and gemcitabine (six models). Thiarabine warrants future clinical trials with leukemias/lymphomas.

引用

页码：647 / 660

页数：14

共 50 条

[1] Preclinical antitumor activity of the MEK inhibitor R05068760 in human tumor xenograft models
Brian, Higgins
Kolinsky, Kenneth
Daouti, Sherif
Rizzo, Christine
Wang, Huisheng
Huby, Nicholas
Niu, Huifeng
Packman, Kathryn
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[2] Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma
Carvalho Santos, Juliana
Profitos-Peleja, Nuria
Lima Ribeiro, Marcelo
Roue, Gael
CANCERS, 2022, 14 (22)
[3] Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia
Uno, Shinsuke
Kinoshita, Yasuko
Azuma, Yumiko
Tsunenari, Toshiaki
Yoshimura, Yasushi
Iida, Shinichiro
Kikuchi, Yasufumi
Yamada-Okabe, Hisafumi
Fukushima, Naoshi
ONCOLOGY REPORTS, 2007, 17 (05) : 1189 - 1194
[4] Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models
Ouchi, KF
Yanagisawa, M
Sekiguchi, F
Tanaka, Y
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (05) : 693 - 702
[5] Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models
Kaori F. -Ouchi
Mieko Yanagisawa
Fumiko Sekiguchi
Yutaka Tanaka
Cancer Chemotherapy and Pharmacology, 2006, 57 : 693 - 702
[6] Antitumor activity of lenvatinib mesilate in human hepatocellular carcinoma preclinical models
Matsuki, Masahiro
Yamamoto, Yuji
Hoshi, Taisuke
Kimura, Takayuki
Funahashi, Yasuhiro
Matsui, Junji
CANCER RESEARCH, 2017, 77
[7] Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models
Fujimoto-Ouchi, Kaori
Sekiguchi, Fumiko
Yasuno, Hideyuki
Moriya, Yoichiro
Mori, Kazushige
Tanaka, Yutaka
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (06) : 795 - 805
[8] Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models
Kaori Fujimoto-Ouchi
Fumiko Sekiguchi
Hideyuki Yasuno
Yoichiro Moriya
Kazushige Mori
Yutaka Tanaka
Cancer Chemotherapy and Pharmacology, 2007, 59 : 795 - 805
[9] Preclinical antitumor activity of a nanoparticulate SN38-polymeric micelle formulation in mouse xenograft models
Tseng, H.
Chou, S.
Wang, C.
Chang, Y.
Hsueh, C.
Lu, M.
Wang, S.
Hsu, Y.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S257 - S257
[10] Xenograft models for the preclinical evaluation of new therapies in acute leukemia
Lee, Erwin M.
Bachmann, Petra S.
Lock, Richard B.
LEUKEMIA & LYMPHOMA, 2007, 48 (04) : 659 - 668

← 1 2 3 4 5 →